SA

Shaikh Abdul Rehman Shaikh Moinoddin

Active Director Director DIN 10847562
DIN 10847562 First appointment Nov 2024
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Shaikh Abdul Rehman Shaikh Moinoddin

Data last updated:

Shaikh Abdul Rehman Shaikh Moinoddin is a Director at Drogon Pharmaceutical Private Limited (since 2024).

DIN 10847562
Primary Designation Director
First Appointment 22 Nov 2024
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director22 Nov 20242024Active

Board colleagues of Shaikh Abdul Rehman Shaikh Moinoddin

NameDINCompanyDesignation
Mohd Maz Ishrat Husain10847561Drogon Pharmaceutical Private LimitedDirector

Directorship timeline

Open interactive timeline →
Drogon Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Shaikh Abdul Rehman Shaikh Moinoddin

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Shaikh Abdul Rehman Shaikh Moinoddin

Shaikh Abdul Rehman Shaikh Moinoddin currently holds 1 directorship: Drogon Pharmaceutical Private Limited (Director, since 22 Nov 2024).

Shaikh Abdul Rehman Shaikh Moinoddin was first appointed on 22 Nov 2024 as Director at Drogon Pharmaceutical Private Limited.

The current boards of Shaikh Abdul Rehman Shaikh Moinoddin's companies include Mohd Maz Ishrat Husain (Drogon Pharmaceutical Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available